NEW YORK (GenomeWeb News) – Agendia and Agilent Technologies announced today that they have extended a supply agreement and intend to collaborate on the development of new in vitro diagnostic tests.
According to a joint statement, the firms will collaborate on developing cancer diagnostic tests that will be run on Agilent microarrays.
In February 2007, Amsterdam, Netherlands-based Agendia received US Food and Drug Administration clearance for its MammaPrint diagnostic for breast cancer recurrence. The test, which is performed on an Agilent microarray, was the first in vitro diagnostic multivariate index assay device approved by the FDA since the agency released a draft guidance in 2006 describing such products.
The partners also announced that Agendia’s products will continue to be supplied on Agilent microarrays through Dec. 31, 2011. Agilent has been manufacturing the components for the Agendia assay since 2003, the firms said.
"We eagerly anticipate expanding our role beyond the manufacturing of Agendia products on the Agilent microarrays to helping them build validated diagnostic cancer tests, as well as developing and expanding the company's worldwide distribution channels,” Yvonne Linney, vice president and general manager of genomics for Santa Clara, Calif.-based Agilent, said in the statement.
Financial terms of the agreements were not disclosed.